AIM ImmunoTech(DE:HXB)
€6.090.00 (0.00%)
DE:HXB
AIM ImmunoTech stock drug pipeline
€6.09
At close:0.00 (0.00%)
AIM ImmunoTech (HXB) Drug Pipeline
1 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Rintatolimod | Long Covid, Post Covid-19 Condition | Phase II | Completed | Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions | Oct 20, 2022 | ― |
| Rintatolimod | Pancreatic Cancer | Phase II | Suspended | Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC | Aug 08, 2022 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Rintatolimod | Phase II | Long Covid, Post Covid-19 Condition | Completed | Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions | Oct 20, 2022 | ― |
| Rintatolimod | Phase II | Pancreatic Cancer | Suspended | Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC | Aug 08, 2022 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Aim Immunotech Inc. (DE:HXB) have in its pipeline
AIM ImmunoTech DE:HXB is currently developing the following drugs: Rintatolimod. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
